Published research on Doxycycline
4 peer-reviewed publications on Doxycycline in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In a pilot study of 15 early breast cancer patients (9 treated with oral doxycycline for 14 days before surgery, 6 untreated controls), post-treatment tumor samples showed a statistically significant decrease in the stemness marker CD44 in 8 of 9 treated patients, with similar results for ALDH1, while markers of proliferation, apoptosis and angiogenesis were unchanged.
- Clinical trial
In 27 patients with ocular adnexal MALT lymphoma given a 3-week course of doxycycline, the overall response rate was 48% (6 complete and 7 partial responses) and the 2-year failure-free survival rate was 66%, with responses seen in both Chlamydia psittaci DNA-positive and DNA-negative patients.
- In vitro
The authors reported that several classes of approved antibiotics that inhibit mitochondrial biogenesis, including doxycycline, reduced cancer stem cell expansion in 12 cancer cell lines across 8 tumor types, with little toxicity to normal cells.
- In vitro
Doxycycline reduced DNA-PK protein expression by more than 90% and radiosensitized breast cancer stem-like cells by up to 4.5-fold, while also reducing mitochondrial and glycolytic activity and blocking several stem cell signaling pathways in mammosphere cultures.
Doxycycline in the catalog (specifications, pack sizes, Certificate of Analysis)